David W. Hilbert

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Immunology and Microbiology · Life Sciences

19h-index1.9kcitations49works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Reproductive tract infections research(14), Urinary Tract Infections Management(9), Antibiotic Resistance in Bacteria(8), Antibiotics Pharmacokinetics and Efficacy(7), Bacteriophages and microbial interactions(7)

Publications49 total

P-445. Susceptibility and molecular characterization of isolates from a Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in pediatric participants with gram-negative (GN) bacterial infection
Open Forum Infectious Diseases·2026Open Access
Erratum to “Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial” [Virology 613 (2026) 110710]
Virology·2025Open Access
Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial
Virology·2025
Correction: A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
Pulmonary Therapy·2025Open Access
A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
Pulmonary Therapy·2025· 4 citedOpen Access
P-1928. Virologic and Clinical Outcomes Among Participants Hospitalized in a Phase 3 Trial Comparing Molnupiravir with Placebo for Treating Mild-to-Moderate COVID-19
Open Forum Infectious Diseases·2025Open Access
2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-<i>Morganellaceae</i> Enterobacterales (NME) in the United States – SMART 2019-2021
Open Forum Infectious Diseases·2023Open Access
2154. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical <i>P. aeruginosa</i> Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021
Open Forum Infectious Diseases·2023Open Access
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
BMC Microbiology·2023· 15 citedOpen Access
2051. Relebactam enhances Imipenem activity across the Imipenem susceptibility spectrum among <i>Pseudomonas aeruginosa</i> isolates collected in the United States--SMART 2018-2020
Open Forum Infectious Diseases·2022Open Access
<i>In Vitro</i> Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020
Antimicrobial Agents and Chemotherapy·2022· 37 citedOpen Access
1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible <i>Pseudomonas aeruginosa</i> and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
Open Forum Infectious Diseases·2021· 1 citedOpen Access
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
Clinical and Translational Science·2021· 30 citedOpen Access
Bacterial Vaginosis–Associated Bacteria and Uterine Fibroids: A Nested Case-Control Study
Sexually Transmitted Diseases·2021· 8 citedOpen Access
1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
Open Forum Infectious Diseases·2020· 4 citedOpen Access
Mycoplasma genitalium and Bacterial Vaginosis–Associated Bacteria in a Non–Clinic-Based Sample of African American Women
Sexually Transmitted Diseases·2020· 3 citedOpen Access
Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)
Bioorganic & Medicinal Chemistry Letters·2018· 9 citedOpen Access
Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity
Antimicrobial Agents and Chemotherapy·2018· 17 citedOpen Access
Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)
Bioorganic & Medicinal Chemistry Letters·2018· 9 citedOpen Access
Trichomonas vaginalis is most frequently detected in women at the age of peri-/premenopause: an unusual pattern for a sexually transmitted pathogen
American Journal of Obstetrics and Gynecology·2017· 22 cited
page 1 of 3Next →

Frequent Co-authors

Eli Mordechai(19), Martin E. Adelson(19), Scott E. Gygax(17), Katherine Young(8), Jack D. Sobel(7), Jason P. Trama(7), C Andrew DeRyke(7), Patrick J. Piggot(6), Jessica A. Schuyler(6), William L. Smith(5), Mary Motyl(5), Carisa S De Anda(5), Sean G. Chadwick(4), Michelle Brown(4), Teresa E. Paulish-Miller(3), Geoffrey Toner(3), Vasant K. Chary(3), Sibylle Lob(3), Fakhar Siddiqui(3), Daniel F. Sahm(3)